Today's reviewed stocks include Applied DNA Sciences Inc. (OTC:APDN), First Titan Corp. (OTC:FTTN), AP Pharma Inc. (OTC:APPA) and RXi Pharmaceuticals Corporation (OTC:RXII).
Applied DNA Sciences Inc. (OTC:APDN) provides botanical-DNA based security and authentication solutions in Europe and the United States. It offers SigNature DNA markers for embedding into a range of products, including various inks, dyes and textile treatments. It was previously known as Datalink Systems, Inc and changed its name to Applied DNA Sciences, Inc. in 2002.
For our complete article on APDN please go here: http://tinyurl.com/OTCmagic-APDN
First Titan Corp. (OTC:FTTN) engages in the exploration and development of oil and natural gas resources worldwide. The company has interests in 1 well in Little Cedar Creek Field in Alabama. First Titan Corp. was established in 2010 and is based in Miramar Beach, Florida. It operates as a subsidiary of Eaton Central America Inc.
For our complete article on FTTN please go here: http://tinyurl.com/OTCmagic-FTTN
AP Pharma Inc. (OTC:APPA) engages in developing pharmaceutical products. These products are used in proprietary Biochronomer polymer-based drug delivery technology. The company’s lead product candidate is APF530, which has completed a Phase III clinical trial. It was previously known as Advanced Polymer Systems, Inc. and changed its name to A.P. Pharma, Inc. in May 2001.
On November 12th, APPA announced that it had initiated a program to expand its pipeline of sustained release products. It includes a new program targeting the relief of post-surgical pain. This time there is no approved 5-HT3 receptor antagonist for the treatment of delayed HEC.
For our complete article on APPA please go here: http://tinyurl.com/OTCmagic-APPA
RXi Pharmaceuticals Corporation (OTC:RXII) is a biotechnology company. It focuses on discovering, developing, and commercializing therapies based on its proprietary, next-generation RNAi platform. Its therapeutic development programs include products for the treatment of ophthalmology, liver disease/liver fibrosis, and amyotrophic lateral sclerosis.
On November 13th, RXII announced that the first patient had been enrolled in a Phase 2 study with the anti-scarring product RXI-109. Patients will receive RXI-109 or placebo on a blinded basis at the distal ends of their revised scar. This system allows for intra-subject comparison of the three revised scar segments.
For our complete article on RXII please go here: http://tinyurl.com/OTCmagic-RXII
OTCMAGIC is a newsletter that reports on developments in the world of penny stocks. OTCMagic is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit OTCMagic.com website, for complete risks and disclosures.
Subscribe Here: http://www.otcmagic.com/
Contact Info:
OTCMagic
info@otcmagic.com